Clinical Trial Update: A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis. [Phase 3]

View source ↗

Summary

A completed Phase 3 trial evaluating the efficacy and safety of RC18, a TACI-antibody fusion protein, in patients with moderate to severe rheumatoid arthritis w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• RC18 (RC18)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Moderate and Severe RheumatoId Arthritis | Phase 3 | Status: COMPLETED